DCF Advisers LLC Acquires 3,250 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

DCF Advisers LLC grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 22.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,750 shares of the company’s stock after buying an additional 3,250 shares during the quarter. DCF Advisers LLC’s holdings in Viridian Therapeutics were worth $231,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in VRDN. Quest Partners LLC grew its holdings in Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after acquiring an additional 4,692 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after purchasing an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC lifted its holdings in Viridian Therapeutics by 108.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after buying an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after buying an additional 1,688 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC boosted their target price on Viridian Therapeutics from $30.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, September 10th. Wolfe Research initiated coverage on shares of Viridian Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $29.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a report on Thursday. Finally, The Goldman Sachs Group raised their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $35.30.

Insider Activity

In related news, Director Fairmount Funds Management Llc bought 1,600,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the acquisition, the director now owns 3,445,813 shares of the company’s stock, valued at approximately $64,608,993.75. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.65% of the stock is currently owned by company insiders.

Viridian Therapeutics Trading Up 6.8 %

VRDN opened at $22.50 on Friday. The firm’s fifty day moving average is $15.93 and its two-hundred day moving average is $15.05. The firm has a market cap of $1.44 billion, a PE ratio of -5.00 and a beta of 1.03. Viridian Therapeutics, Inc. has a twelve month low of $10.93 and a twelve month high of $24.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.82 and a current ratio of 15.82.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. Equities research analysts anticipate that Viridian Therapeutics, Inc. will post -3.93 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.